Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)

Singapore, May 1 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)'. The following are the other relevant details related to the trial:

Therapeutic Area: Gastroenterology

Trial Centre(s): Changi General Hospital National University Hospital Singapore General Hospital

Trial Status: NA

Principal Investigator(s): Dr Rahul Kumar Dr Mark Dhinesh Muthiah Dr George Goh Boon Bee

Published by HT Digital Content Services with permission from Health Daily Digest...